scispace - formally typeset
Open AccessJournal ArticleDOI

Amyloid precursor protein and endosomal‐lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease

Ralph A. Nixon
- 01 Jul 2017 - 
- Vol. 31, Iss: 7, pp 2729-2743
Reads0
Chats0
TLDR
Growing evidence that implicates AD gene–driven ELN disruptions as not only the antecedent pathobiology that underlies β‐amyloidogenesis but also as the essential partner with APP and its metabolites that drive the development of AD, including tauopathy, synaptic dysfunction, and neurodegeneration is discussed.
Abstract
Abnormalities of the endosomal-lysosomal network (ELN) are a signature feature of Alzheimer's disease (AD). These include the earliest known cytopathology that is specific to AD and that affects endosomes and induces the progressive failure of lysosomes, each of which are directly linked by distinct mechanisms to neurodegeneration. The origins of ELN dysfunction and β-amyloidogenesis closely overlap, which reflects their common genetic basis, the established early involvement of endosomes and lysosomes in amyloid precursor protein (APP) processing and clearance, and the pathologic effect of certain APP metabolites on ELN functions. Genes that promote β-amyloidogenesis in AD (APP, PSEN1/2, and APOE4) have primary effects on ELN function. The importance of primary ELN dysfunction to pathogenesis is underscored by the mutations in more than 35 ELN-related genes that, thus far, are known to cause familial neurodegenerative diseases even though different pathogenic proteins may be involved. In this article, I discuss growing evidence that implicates AD gene-driven ELN disruptions as not only the antecedent pathobiology that underlies β-amyloidogenesis but also as the essential partner with APP and its metabolites that drive the development of AD, including tauopathy, synaptic dysfunction, and neurodegeneration. The striking amelioration of diverse deficits in animal AD models by remediating ELN dysfunction further supports a need to integrate APP and ELN relationships, including the role of amyloid-β, into a broader conceptual framework of how AD arises, progresses, and may be effectively therapeutically targeted.-Nixon, R. A. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease.

read more

Citations
More filters
Journal ArticleDOI

Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease

TL;DR: Current research on the interplay and sequence of oxidative damage related to impaired brain glucose metabolism and proteostasis defects are summarized and potential pharmacological interventions to retard AD progression are suggested.
Journal ArticleDOI

Lysosomes as dynamic regulators of cell and organismal homeostasis

TL;DR: The modulation of lysosome function could be a promising therapeutic strategy for the treatment of cancer as well as metabolic and neurodegenerative disorders.
Journal ArticleDOI

Autophagy in Human Diseases

TL;DR: Autophagy in Human Diseases Autophagy is a complex process of intracellular degradation of senescent or malfunctioning organelles that is associated with certain cancers, neurodeletes, and other diseases.
Journal ArticleDOI

The lysosome as a cellular centre for signalling, metabolism and quality control.

TL;DR: The central role of the lysosome in cellular metabolism, including in macromolecular catabolism and nutrient recycling, and organelle crosstalk is discussed, and the emerging function of theLysosomes as a centre for nutrient sensing and metabolic signal transduction is highlighted.
References
More filters
Journal ArticleDOI

The role of autophagy in neurodegenerative disease

TL;DR: An overview of the role of autophagy in neurodegenerative disease is provided, focusing particularly on less frequently considered lysosomal clearance mechanisms and their considerable impact on disease.
Journal ArticleDOI

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

TL;DR: Evidence from many independent research centers strongly supports the existence of a specific disease, as defined by the presence of A&bgr; plaques and neurofibrillary tangles.
Journal ArticleDOI

CNS synaptogenesis promoted by glia-derived cholesterol

TL;DR: Cholesterol complexed to apolipoprotein E-containing lipoproteins may explain the delayed onset of CNS synaptogenesis after glia differentiation and neurobehavioral manifestations of defects in cholesterol or lipoprotein homeostasis.
Journal ArticleDOI

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers

TL;DR: The cellular prion protein (PrPC) is identified as an amyloid-β-oligomer receptor by expression cloning, and PrPC-specific pharmaceuticals may have therapeutic potential for Alzheimer’s disease.
Related Papers (5)